These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 30741558

  • 1. Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis.
    Sun G, Chen X, Gong U, Chen Y, Li G, Wei F, Jiang A, Niu Y, Shang Z.
    Future Oncol; 2019 Apr; 15(10):1167-1179. PubMed ID: 30741558
    [Abstract] [Full Text] [Related]

  • 2. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
    Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF, STOPCaP Abiraterone Collaborators.
    Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
    [Abstract] [Full Text] [Related]

  • 3. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S, Lang JM, Jarrard DF.
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, Boorjian SA, Kulkarni GS, Karnes RJ, Satkunasivam R.
    Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
    [Abstract] [Full Text] [Related]

  • 5. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
    Wülfing C, Bögemann M, Goebell PJ, Hammerer P, Machtens S, Pfister D, Schwentner C, Steuber T, von Amsberg G, Schostak M.
    Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460
    [Abstract] [Full Text] [Related]

  • 6. Treatment of hormone-naïve metastatic prostate cancer.
    Hamilou Z, Saad F, Fizazi K.
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):334-338. PubMed ID: 30015691
    [Abstract] [Full Text] [Related]

  • 7. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [Abstract] [Full Text] [Related]

  • 8. [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
    Hammerer P, Manka L.
    Urologe A; 2019 Oct; 58(10):1185-1197. PubMed ID: 31127324
    [Abstract] [Full Text] [Related]

  • 9. An up-to-date evaluation of abiraterone for the treatment of prostate cancer.
    Shpilsky J, Stevens J, Bubley G.
    Expert Opin Pharmacother; 2021 Jul; 22(10):1227-1234. PubMed ID: 33856289
    [Abstract] [Full Text] [Related]

  • 10. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
    Landre T, Guetz GD, Chouahnia K, Fossey-Diaz V, Taleb C, Culine S.
    Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case-control study.
    Arafa AT, Blader LR, Ramakrishna K, Engle J, Ryan CJ, Zorko NA, Jha G, Antonarakis ES.
    Prostate; 2023 Sep; 83(13):1279-1284. PubMed ID: 37337669
    [Abstract] [Full Text] [Related]

  • 12. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
    McNamara M, Sweeney C, Antonarakis ES, Armstrong AJ.
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
    [Abstract] [Full Text] [Related]

  • 13. Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.
    Shiota M, Narita S, Akamatsu S, Fujimoto N, Sumiyoshi T, Fujiwara M, Uchiumi T, Habuchi T, Ogawa O, Eto M.
    JAMA Netw Open; 2019 Feb 01; 2(2):e190115. PubMed ID: 30794306
    [Abstract] [Full Text] [Related]

  • 14. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
    Narita S, Kimura T, Hatakeyama S, Hata K, Yanagisawa T, Maita S, Chiba S, Sato H, Kashima S, Koizumi A, Yamamoto R, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Suzuki T, Ohyama C, Egawa S, Nomura K, Habuchi T.
    World J Urol; 2022 May 01; 40(5):1135-1141. PubMed ID: 35218371
    [Abstract] [Full Text] [Related]

  • 15. Intermittent androgen deprivation therapy in advanced prostate cancer.
    Alva A, Hussain M.
    Curr Treat Options Oncol; 2014 Mar 01; 15(1):127-36. PubMed ID: 24395278
    [Abstract] [Full Text] [Related]

  • 16. Recent trends in the management of advanced prostate cancer.
    Ritch C, Cookson M.
    F1000Res; 2018 Mar 01; 7():. PubMed ID: 30345007
    [Abstract] [Full Text] [Related]

  • 17. Treatment of Castration-naive Metastatic Prostate Cancer.
    Hamilou Z, Baciarello G, Fizazi K.
    Eur Urol Focus; 2017 Dec 01; 3(6):518-521. PubMed ID: 29500136
    [Abstract] [Full Text] [Related]

  • 18. Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.
    Xu L, Pachynski RK.
    Curr Urol Rep; 2018 Aug 13; 19(10):79. PubMed ID: 30105573
    [Abstract] [Full Text] [Related]

  • 19. What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis.
    Sun G, Zhang X, Chen J, Liao B, Liu Z, Zhao J, Gao AC, Yang Y, Shu K, Liu J, Zhao P, Shen P, Zeng H.
    Urol Oncol; 2018 Dec 13; 36(12):505-517. PubMed ID: 30316578
    [Abstract] [Full Text] [Related]

  • 20. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
    Kassem L, Shohdy KS, Abdel-Rahman O.
    Curr Med Res Opin; 2018 May 13; 34(5):903-910. PubMed ID: 29490505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.